05.12.2018 • News

Covestro Widens Japanese TPU Stake

Covestro has widened its stake in its thermoplastic polyurethanes (TPU) joint venture with Japanese PPS compounder and pigment manufacturer DIC (formerly Dainippon Ink & Chemicals), increasing its holding to 80% from 50%.

Covestro Widens Japanese TPU Stake (c) Covestro
Covestro Widens Japanese TPU Stake (c) Covestro

The company was founded in 2000 as a 50:50 jv between Dainippon and the German engineering plastics producer’s s former parent Bayer. Kimiyasu Yonemaru, president of Covestro Japan, said the increased shareholding“ shows a clear commitment” to the Japanese market.

Covestro said the share purchase reflects the company’s plans to expand its global TPU business and complements its recent global capacity expansion at New Martinsville, West Virginia, USA, and Changhua, Taiwan. Capacity at each site was widened by 25%.

The Leverkusen-based player ranks among the top three global producers of TPU, a business that accounted for about 10% in sales for its Coatings, Adhesives, Specialties (CAS) segment last year.

Markus Steilemann, CEO since mid-2018, estimates growth of the global TPU sector at around 6% annually, with the double-digit core volume growth of Covestro’s own business – which encompasses specialties used in applications such as automotive, electric appliance, IT, health care and sports – outpacing the market’s long-term average.

The Japanese group will continue to support the joint venture with feedstocks and on-site services. Production as well as research and development, will continue to be based at DIC’s facility in Sakai, Osaka Prefecture. DIC also cooperates with Covestro in other of coatings and additives activities.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read